This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

GUSTO III trial

Authoring team

15059 patients presenting within 6 hours of the onset of symptoms of acute myocardial infarction were randomized to treatment with reteplase or alteplase.

Reteplase was administered as two boluses of 10 MU separated by 30 min. Alteplase was given as an accelerated infusion of up to 100 mg over 90 min.

Mortality at 30 days was:

  • 7.47% for reteplase
  • 7.24% for alteplase
  • p=0.54, 95% confidence interval for absolute difference in mortality rates -1.1 to 0.66%

The rate of complications was the same in both arms.

Reteplase may be given as a bolus and hence may be more convenient, however alteplase is as effective.

Reference:

  • The GUSTO investigators. (1997). A comparison of reteplase with alteplase for acute myocardial infarction. New Engl. J. Med. 337, 1118-23.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.